Veracyte, Inc.

VCYT·NasdaqGM·Healthcare
Compare
52.52+2.23 (+4.43%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
Pre-market38.27−14.25 (−27.13%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close50.29
Open52.35
Day range49.2952.76
52-week range29.4660.91
Off day high−0.45%
Off 52-week high−13.77%
Volume1.83M
Avg. volume (3M)1.29M
Market cap4.22B
EPS (TTM)1.40
Forward P/E27.03
P/E ratio (TTM)37.51
Dividend yield—
Beta (5Y)1.96
Shares outstanding80.39M
Short interest14.44% of float
Earnings dateNov 4, 2026
Analyst target59.73
Profit margin20.37%

Against its peers

Compare in full ›
VCYT 300463.SZ RDNT RVTY QGEN NEO
Market cap 4.22B 5.55B 6.32B 17.79B 10.50B 2.22B
P/E (TTM) 37.5 — — 70.9 25.8 —
Forward P/E 27.0 10.6 97.9 26.9 19.5 54.5
Price/book 3.0 0.9 5.8 2.5 3.1 2.8
Dividend yield — — — 0.18% 0.69% —
1-year change +9.23% −23.74% −6.34% +76.60% +14.37% +61.36%
Today +4.43% +1.32% +9.67% −2.48% +0.89% +1.90%

The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.

Latest news

All VCYT news ›
Markets Daily·Positive

Veracyte (NASDAQ:VCYT) Issues Earnings Results

Posted by Kim Johansen on Nov 4th, 2026 Check Out Our Latest Research Report on VCYT Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions.…

Cantech Letter·Positive

Verano Holdings remains undervalued, this analyst says

On Oct. 29, Haywood Securities analyst Neal Gilmer maintained his “Buy” rating and C$18.75 target on Verano Holdings (Verano Holdings Stock Quote, Chart, News, Analysts, Financials NEO:VRNO) following third-quarter results that fell short…

Seeking Alpha·Positive

Veracyte: Strong Diagnostic Growth And Improving Margins

Explore why Veracyte is rated a buy: strong test demand, 15% revenue growth, rising margins, and new product expansion. Click for more on VCYT stock. - Veracyte is rated a buy due to strong diagnostic test demand, robust financials, and…

From the 4Search news index, newest first.

In the news

28mentions in 30 days
26with it in the headline
Positivesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 28 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance